期刊文献+

荧光原位杂交与免疫组织化学检测胃癌组织中HER-2基因及蛋白表达一致性 被引量:9

Consistency of HER-2 expression detected by both immunohistochemistry and fluorescence in situ hybridization in gastric cancer
下载PDF
导出
摘要 目的探讨荧光原位杂交(fluorescence in situ hybridization,FISH)与免疫组织化学(immunohistochemistry,IHC)检测胃癌组织中HER-2基因扩增及与C-erbB-2蛋白表达结果的一致性。方法采用FISH和IHC法分别检测50例胃癌组织中HER-2基因扩增和C-erbB-2蛋白表达,并采用SPSS 19.0进行统计学分析。结果 50例胃癌标本进行IHC检测结果 11例为(﹢),9例为(),4例为(),26例为(-);50例胃癌标本进行FISH检测结果 11例为(+),39例为(-);其中,FISH检测阳性标本中IHC检测有2例(﹢),5例(),4例()。IHC检测C-erbB-2蛋白为()的病例FISH检测均为(+),而IHC检测C-erbB-2蛋白()的9位患者中有4例经FISH检测证实HER-2呈(-),5例呈(+)。结论 IHC与FISH检测HER-2状态结果的符合率为95.1%(39/41),具有高度一致性(Kappa系数=0.773,P<0.001)。当IHC检测C-erbB-2蛋白表达为(-)或()时IHC和FISH检测结果有较高符合率,可作为临床是否应用Herceptin治疗的依据,而C-erbB-2蛋白表达为()的病例则必须进一步行HER-2基因扩增检测。 Purpose To investigate the consistency of HER-2 expression in gastric carcinoma by fluorescence in situ hybridization(FISH) and immunohistochemistry(IHC).Methods The expression of C-erbB-2 protein and HER-2 gene amplification in 50 cases of gastric cancer were detected by IHC and FISH,respectively,and the concordance between them was analyzed by SPSS 19.0.Results The expression of C-erbB-2 protein was negative,weak,moderately and strongly positive in 26,11,9 and 4 cases,respectively,by IHC.11 cases were HER-2 gene positive in FISH,among which 2,5 and 4 cases were weak,moderately and strongly positive in IHC respectively.All of 4 cases with strongly positive C-erbB-2 expression by IHC were positive in FISH.However,HER-2 gene amplification existed in 5 cases among 9 cases with moderately positive C-erbB-2 expression by IHC.Conclusions The concordance rate in our investigation between IHC and FISH of HER-2 is 95.1%,with a high degree of consistency(Kappa coefficient 0.773,P0.001).In addition,the results of IHC and FISH have a higher coincidence rate in the cases with strongly positive or negative(negative or weak positive) expression of C-erbB-2.It can be an indication to decide whether herceptin can be used in clinical therapy or not.But in the cases with moderately positive expression of C-erbB-2,the results of FISH are diversified,indicating these cases need further detection by FISH.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2012年第10期1094-1097,共4页 Chinese Journal of Clinical and Experimental Pathology
关键词 胃肿瘤 HER-2/C-erbB-2 荧光原位杂交 免疫组织化学 gastric neoplasms HER-2/C-erbB-2 fluorescence in situ hybridization immunohistochemistry
  • 相关文献

参考文献13

  • 1廖志东,郑少秋,匡亚玲,朱文标,谢寿城,吴国武.HER-2、HIF-1a、GLUT-1及VEGF表达在乳腺浸润性导管癌淋巴结转移中作用[J].临床与实验病理学杂志,2012,28(1):22-25. 被引量:12
  • 2Bao W, Fu H J, Jia L T, et al. HER-2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion[J]. Arch Biochem Biophys, 2010,499 ( 1 - 2) :49 - 55.
  • 3张海娥,庄暨军,贺卫东.BRMS1与HER-2基因在乳腺癌中的研究进展[J].临床与实验病理学杂志,2009,25(1):89-91. 被引量:1
  • 4Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab incombination with chemotherapy versus chemotherapy alone fortreatment of HER-2-positive advanced gastric or gastro-oesophagealjunction cancer (ToGA ) : a phase 3,open-label, randomised con-trolled trial[J]. Lancet, 2010,376(9742) :687 -97.
  • 5Choritz H, Busche G, Kreipe H. Quality assessment of HER-2testing by monitoring of positivity rates [ J ]. Virchows Arch,2011,459(3) :283 -9.
  • 6胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557. 被引量:97
  • 7Mrklic I,Bendic A, Kunac N,et al. Her-2/neu assessment forgastric carcinoma : validation of scoring system [ J ]. Hepatogastro-enterology, 2012,59(113):300 -3.
  • 8O'Grady A, Allen D, Happerfield L, et al. An immunohistochem-ical and fluorescence in situ hybridization-based comparison be-tween the oracle HER-2 bond immunohistochemical system, DakoHercepTest, and Vysis PathVysion HER-2 FISH using both com-mercially validated and modified ASCO/CAP and United KingdomHER-2 IHC scoring guidelines [ J]. Appl Immunohistochem MolMoiphol, 2010,18(6) :489 -93.
  • 9陈万青.2004-2005年中国恶性肿瘤发病与死亡的估计[J].中华肿瘤杂志,2009,31(9):664-668. 被引量:136
  • 10Weissinger F, Reymond M, Dumke K, Kruger M. Successfultreatment of a patient with HER-2-positive metastatic gastric cancerwith third-line combination therapy with irinotecan, 5 -fluorouracil,leucovorin and trastuzumab ( FOLFIRI-T) [ J]. Onkologie,2011,34(10):548 -51.

二级参考文献46

  • 1唐鲁兵,高海东,刘焕涛,马榕,余之刚,孙靖中.BRMS1 mRNA在乳腺癌中的表达与腋淋巴结转移的关系[J].山东大学学报(医学版),2005,43(12):1163-1165. 被引量:13
  • 2Seraj M J, Samant R S, Verderame M F,et al. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMSI, encoded at chromosome 11 q13 [ J ]. Cancer Res, 2000,60 ( 11 ) : 2764.
  • 3Samant R S, Debies M T, Shevde L A, et al. Identification and characterization of the murine ortholog ( brmsl ) of breast-cancer metastasis suppressor 1 ( BRMS1 ) [ J]. Int J Cancer,2002,97 ( 1 ) : 15.
  • 4Nikolaev A Y, Papanikolaou N A, Li M, et al. Identification of a novel BRMSl-homologue protein p40 as a component of the mSin3A/ p33 ( IN Glb)/HDAC1 deacetylase complex [J ]. Biochem Biophys Res Commun,2004,323(4) :1216.
  • 5Slamon D J, CIark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survivalwith amp lification of the HER-2/ neuoncogene [ J ]. Science, 1987,235 (4785) : 177 - 182.
  • 6Lohrish C, PiccartM. An overview of HER-2 [ J ]. Semin Oncol, 2001,28:3 - 11.
  • 7Wingens M,Walma T,Van Ingen H,et al. Structural analysis of an epidermal growth factor/transforming growth factoralpha chimera with unique ErbB binding specificity[ J]. J Biol Chem,2003,278 (40) :39114 - 39123.
  • 8Cicek M, Samant R S, Kinter M, et al. Identfication of metastasisassociated proteins through protein analysis of metastatic MDA-MB- 435 cells [ J ]. Clin Exp Metastasis,2004,21 ( 2 ) : 149.
  • 9Stark A M, Tongers K, Maass N, et al. Reduced metastasis suppressor gene mRNA expression in breast cancer brain metastases[ J]. J Cancer Res Clin Oncol, 2005,131 ( 3 ) : 191.
  • 10Zhang S, Lin Q D, DI W. Suppression of human ovarian carcinoma metastasis by the metastasis suppressor gene, BRMS1 [ J ]. Int J Gynecol Cancer,2006,16(2) :522.

共引文献238

同被引文献83

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1363
  • 2Chao He,Xue-Yi Bian,Xing-Zhi Ni,Dan-Ping Shen,Yan-Ying Shen,Hua Liu,Zhi-Yong Shen,Qiang Liu.Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer[J].World Journal of Gastroenterology,2013,19(14):2171-2178. 被引量:28
  • 3姜洋,金晓明,屠康.平均阳性染色面积百分比法分析免疫组化结果初探[J].生物医学工程学杂志,2007,24(3):650-653. 被引量:43
  • 4沈丹华,王凤华,虞有智.显色原位杂交检测乳腺癌HER2基因扩增的应用价值[J].中华病理学杂志,2007,36(7):457-460. 被引量:3
  • 5Hofmann M, Stoss O, Shi D, et al. Assessment of a HEP,2 scoring system for gastric cancer: results from a validation study[ JJ. Histo- pathology,2008,52:797 -805.
  • 6Middleton LP, Price KM, Puig P, et al. Implementation of Ameri- can Society of Clinical Oncology/College of American Pathologists HER2 Guideline Rec - ommendations in a tertiary care facility in- creases HER2 immunohistochemistry and fluorescence in situ hybrid- ization concordance and decreases thenum[ J]. Archives of Pathology and Laboratory Medicine,2009,133:775 -780.
  • 7Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA) : a phase 3, open-label, randomised con- trolled trial [ J ]. Lancet, 2010,376 ( 9742 ) :687 - 97.
  • 8Hofmann M, Stoss O, Shi D. Assessment of a HER2 scoring sys- tem for gastric cancer: results from a validation study[ J]. Histo- pathology, 2008,52 (7) :797 - 805.
  • 9Liang Z, Zeng X, Gao J, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocar- cinoma from Chinese patients[ J]. BMC Cancer, 2008,8:363.
  • 10Hsu J T, Chen T C, Tseng J H, et al. Impact of HER-2 overex- pression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients[ J ]Oncologist, 2011,16 ( 12 ) : 1706 - 13.

引证文献9

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部